Latest Heart transplantation Stories
TUCSON, Ariz., Oct. 18, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that San Raffaele Hospital in Milan, Italy, has discharged its first patient to receive the SynCardia temporary Total Artificial Heart. On Sept. 7, 55-year-old Marco Fumagalli left the hospital to wait for a matching donor heart at home using the Freedom® portable...
TUCSON, Ariz., Oct. 11, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that revenue and implants for the first nine months of 2012 have exceeded the company's best 12-month totals to date. The quarter ended Sept. 30 marks SynCardia's sixth consecutive profitable quarter. (Photo: http://photos.prnewswire.com/prnh/20121011/LA90890)...
TUCSON, Ariz., Oct. 4, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University Medical Center (UMC) Ljubljana has transplanted Slovenia's first patient to receive the SynCardia temporary Total Artificial Heart. The patient, 61-year-old Nikola Gaspic, received a matching donor heart on July 1, after 256 days of life with the Total...
TUCSON, Ariz., Sept. 20, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the first patient to receive the SynCardia temporary Total Artificial Heart at Ankara University Heart Center in Turkey has been discharged from the hospital. The patient, 47-year-old Arif Sahin, is currently waiting for a matching donor heart with his family...
TUCSON, Ariz., Sept. 13, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that University of Kentucky (UK) Medical Center has successfully transplanted its first patient to receive the SynCardia temporary Total Artificial Heart. Zack Poe, 21, received his matching donor heart in July after five months of life with the Total Artificial...
ALEXANDRIA, Va., Sept. 12, 2012 /PRNewswire/ -- Oxford Finance LLC ("Oxford"), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced a $15 million round of debt financing for XDx, Inc. Silicon Valley Bank acted as co-lender in this transaction. Proceeds of the loan will be used for working capital and to fund the development of new diagnostic applications using XDx's molecular expression technology. "XDx is a pioneer...
TUCSON, Ariz., Aug. 23, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Michelle Johnson, a 39-year-old mother of three who received the SynCardia temporary Total Artificial Heart in January, is featured in the cover story of U.S. News & World Report's "Best Hospitals" issue. The 2012-2013 guidebook to the nation's top hospitals...
TUCSON, Ariz., Aug. 15, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Evangelischen und Johanniter Klinikum Niederrhein (EJK Duisburg) in Germany has become one of the most active SynCardia Certified Centers in Europe. (Photo: http://photos.prnewswire.com/prnh/20120815/LA57714) "End-stage biventricular heart failure is a lethal...
TUCSON, Ariz., Aug. 9, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart, announced today record-setting revenue for the quarter ended June 30, 2012, marking the company's best quarter to date and its fifth consecutive profitable quarter. (Photo: http://photos.prnewswire.com/prnh/20120809/LA54747) "Although many companies in the mechanical circulatory support space...
THE WOODLANDS, Texas, Aug. 9, 2012 /PRNewswire/ -- Berlin Heart announced today that a study published in the current issue of the New England Journal of Medicine (NEJM) concludes that survival using the Company's EXCOR(®) Pediatric Ventricular Assist Device (VAD) is "significantly greater" than the standard-of-care (extracorporeal membrane oxygenation, or "ECMO") as a "bridging therapy" for children in need of a heart transplant. The principal author, Charles D. Fraser, Jr.,...
Latest Heart transplantation Reference Libraries
The artificial heart, a mechanical heart replacement, is typically used in order to bridge the time to heart transplant or to replace the heart in case a transplant is impossible. Often ventricular assist devices are confused with mechanical hearts because the assist the heart through pumps. They are also different from a cardiopulmonary bypass machine which is an external device used to provide the function of the heart and lungs. CPBs are usually only used for a few hours at a time,...
